Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a gene-editing company’s disclosures can feel like lab work. CRISPR Therapeutics’ 10-K alone weaves R&D spending, milestone payments, and clinical data into hundreds of pages. Our platform turns that complexity into clarity: CRISPR Therapeutics SEC filings explained simply.
Stock Titan’s AI combs every CRISPR Therapeutics quarterly earnings report 10-Q filing to surface cash-burn trends, collaboration revenue, and pipeline progress, while side-by-side charts deliver CRISPR Therapeutics earnings report filing analysis in minutes. Need to react quickly to trial updates? You’ll see CRISPR Therapeutics 8-K material events explained within moments of hitting EDGAR. For annual deep dives, our summary of the CRISPR Therapeutics annual report 10-K simplified highlights manufacturing scale-up plans and key risk factors.
- Instant alerts on CRISPR Therapeutics Form 4 insider transactions real-time, so you can track every CRISPR Therapeutics executive stock transactions Form 4 and spot sentiment shifts.
- Clear answers to “How do I read the CRISPR Therapeutics proxy statement executive compensation?” with plain-English AI notes.
- Guided walkthroughs for understanding CRISPR Therapeutics SEC documents with AI, saving hours of manual review.
Whether you’re checking CRISPR Therapeutics insider trading Form 4 transactions before a catalyst event or validating dilution risk, our tool delivers comprehensive coverage, real-time updates, and context that matters to gene-editing investors.
CRISPR Therapeutics director Douglas A. Treco reported open-market activity on 08/06/2025, purchasing and selling shares of CRSP. The filing discloses an open-market purchase of 20,000 common shares and a reported disposition of 22,000 common shares. The filing lists a weighted average price of $57.03 and notes the sales occurred in multiple transactions at prices ranging from $56.92 to $57.16. The report states the purchases were made in accordance with the issuer's trading policies.
The form identifies Treco as a director and was submitted through an attorney-in-fact. The filing contains no financial results or forward guidance; it documents only the insider transactions and the price range for the reported sales.
CRISPR Therapeutics (Nasdaq: CRSP) filed an 8-K reporting new in-vivo cardiovascular data.
CTX310: Phase 1 trial shows up to 82% triglyceride and 86% LDL-C reductions at 0.8 mg/kg, with no clinically significant liver-enzyme changes.
CTX320: Phase 1 enrollment ongoing; next clinical update shifted to H1 2026 to incorporate emerging Lp(a) insights.
CTX340: IND/CTA-enabling studies progressing for refractory hypertension.
The company highlights validated surrogate endpoints, a favorable safety profile, and includes customary forward-looking statement disclaimers.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
